Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells.

[1]  Yoonkyung Kim,et al.  Cholesterol inhibits MMP‐9 expression in human epidermal keratinocytes and HaCaT cells , 2007, FEBS letters.

[2]  Y. Hsieh,et al.  Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. , 2006, Toxicology and applied pharmacology.

[3]  Christopher M. Overall,et al.  Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer , 2006, Cancer and Metastasis Reviews.

[4]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[5]  R. Agarwal,et al.  Silymarin and silibinin cause G1 and G2–M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin , 2006, Oncogene.

[6]  C. Haglund,et al.  Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer , 2006, Journal of Clinical Pathology.

[7]  G. Basu,et al.  Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. , 2004, Molecular cancer research : MCR.

[8]  Y. Surh,et al.  Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. , 2004, Biochemical pharmacology.

[9]  L. Ellis,et al.  Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. , 2003, Cancer research.

[10]  R. Agarwal,et al.  Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. , 2003, Anticancer research.

[11]  R. Agarwal,et al.  Flavonoid antioxidant silymarin and skin cancer. , 2002, Antioxidants & redox signaling.

[12]  T. Tanabe,et al.  Cyclooxygenase isozymes and their gene structures and expression. , 2002, Prostaglandins & other lipid mediators.

[13]  L. Norton,et al.  Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer , 2002, The Journal of Biological Chemistry.

[14]  T. Chan,et al.  Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. , 2002, The Lancet. Oncology.

[15]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[16]  J. Fargnoli,et al.  Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. , 2001, Cancer research.

[17]  Y. Surh,et al.  Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. , 2001, Mutation research.

[18]  M. Hori,et al.  Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. , 2001, Journal of experimental & clinical cancer research : CR.

[19]  M. Vincenti,et al.  Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. , 2000, Cytokine.

[20]  R. Agarwal,et al.  Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. , 1999, Cancer letters.

[21]  R. Agarwal,et al.  Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Y. Yatabe,et al.  Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Q. Sang,et al.  Complex role of matrix metalloproteinases in angiogenesis , 1998, Cell Research.

[24]  R. Muschel,et al.  Tumor cell contact mediated transcriptional activation of the fibroblast matrix metalloproteinase-9 gene: involvement of multiple transcription factors including Ets and an alternating purine-pyrimidine repeat , 1998, Clinical & Experimental Metastasis.

[25]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[26]  J. Guillem,et al.  Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells. , 1996, British Journal of Cancer.

[27]  H. Herschman.  Prostaglandin synthase 2. , 1996, Biochimica et biophysica acta.

[28]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[29]  G. Murphy,et al.  Matrix metalloproteinases and their inhibitors. , 1995, Acta orthopaedica Scandinavica. Supplementum.

[30]  K. Seibert,et al.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L. Liotta,et al.  Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  L. Marnett,et al.  COX-2: a target for colon cancer prevention. , 2002, Annual review of pharmacology and toxicology.